DuPont (DD) (IHG) (ALTR) (LSCC) (XLNX) (ONXX) (COLM) (FRAN) (AMTG) Get New Coverage

DuPont (NYSE:DD), Intercontinental Hotels Group (NYSE:IHG), Altera (NASDAQ:ALTR), Lattice Semiconductor (NASDAQ:LSCC), Xilinx (NASDAQ:XLNX), Onyx Pharmaceuticals (NASDAQ:ONXX), Columbia Sportswear (NASDAQ:COLM), Francesca’s (NASDAQ:FRAN) and Apollo Residential Mortgage (NYSE:AMTG) getting new coverage from analysts.

Barclays initiated coverage on DuPont (DD). They have an "Equal Weight" rating on the company.

Jefferies (NYSE:JEF) initiated coverage on Intercontinental Hotels Group (IHG). They have a "Buy" rating on the company

Pacific Crest initiated coverage on Altera (ALTR). They have an "Outperform" rating on the company and a price target of $50.

Pacific Crest initiated coverage on Lattice Semiconductor (LSCC). They have an "Outperform" rating on the company and a price target of $9.

Pacific Crest initiated coverage on Xilinx (XLNX). They have a "Market Perform" rating on the company.

Brean Murray initiated coverage on Onyx Pharmaceuticals (ONXX). They have a "Hold" rating on the company.

FBR Capital initiated coverage on Columbia Sportswear (COLM). They have a "Market Perform" rating and price target of $61 on the company.

Goldman Sachs (NYSE:GS) initiated coverage on Francesca’s (FRAN). They have a "Neutral" rating and price target of $32 on the company.

JP Morgan (NYSE:JPM) initiated coverage on Apollo Residential Mortgage (AMTG). They have a "Neutral" rating on the company.

Tyson (TSN) (ADM) (SFD) (BG) (OILT) (ONXX) Get New Coverage

Tyson Foods, Inc. (NYSE: TSN), Archer Daniels Midland Company (NYSE: ADM), Smithfield Foods, Inc. (NYSE: SFD), Bunge Limited (NYSE: BG), Oiltanking Partners (NASDAQ: OILT) and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) getting new analyst coverage.

Barclays Capital initiated coverage on Tyson Foods, Inc. (TSN). They placed an “Overweight” rating and a price target of $23.00 on the company.

Barclays Capital initiated coverage on Archer Daniels Midland Company (ADM). They placed an “Equal Weight” rating and a price target of $31.00 on the company.

Barclays Capital initiated coverage on Smithfield Foods, Inc. (SFD). They placed an “Equal Weight” rating and a price target of $23.00 on the company.

Barclays Capital initiated coverage on Bunge Limited (BG). They placed an “Overweight” rating and a price target of $81.00 on the company.

Barclays Capital initiated coverage on Oiltanking Partners (OILT). They placed an “Overweight” rating and a price target of $28.00 on the company.

Summer Street initiated coverage on Onyx Pharmaceuticals, Inc. (ONXX). They placed a “Buy” rating and a price target of $49.00 on the company.

Onyx (ONXX) (MINI) (AVNR) (MGRC) (HGSI) (OILT) (MDGN) Get New Coverage

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Mobile Mini, Inc. (NASDAQ: MINI), Avanir Pharmaceuticals Inc (NASDAQ: AVNR), Mcgrath Rentcorp (NASDAQ: MGRC), Human Genome Sciences (NASDAQ: HGSI), Oiltanking Partners (NASDAQ: OILT) and Medgenics (NASDAQ: MDGN) getting new analyst coverage.

Keybanc initiated coverage on Mobile Mini, Inc. (MINI). They placed a “Hold” rating on the company.

Summer Street Research initiated coverage on Onyx Pharmaceuticals, Inc. (ONXX). They placed a “Buy” rating and a price target of $49.00 on the company.

JMP Securities initiated coverage on Avanir Pharmaceuticals Inc (AVNR). They placed an “outperform” rating and a price target of $7.00 on the company.

Keybanc initiated coverage on Mcgrath Rentcorp (MGRC). They placed a “Buy” rating and a price target of $28.00 on the company.

Brean Murray initiated coverage on Human Genome Sciences (HGSI). They placed a “Buy” rating and a price target of $22.00 on the company.

Raymond James (NYSE:RJF) initiated coverage on Oiltanking Partners (OILT). They placed an “Outperform” rating on the company.

Maxim Group initiated coverage on Medgenics (MDGN). They placed a “Buy” rating and a price target of $8.00 on the company.

Big Movers (INFY) (SM) (PTR) (ONXX) (EOC) on May 6

Among the big, positive movers on Friday, May 6, were Infosys Technologies (INFY), Sm Energy Company (SM), Petrochina Company (PTR), Onyx Pharmaceuticals (ONXX) and Empresa Nacional (EOC).

Infosys Technologies (INFY) jumped $1.52, to close at $64.82, a gain of 2.40 percent.

Sm Energy Company (SM) was up $1.51 on the day to close at $65.26, a gain of 2.37 percent.

Petrochina Company (PTR) climbed $1.51 to close at $134.89, a gain of 1.13 percent.

Onyx Pharmaceuticals (ONXX) rose $1.50 to close the session at $39.81, a gain of 3.92 percent.

Empresa Nacional (EOC) was up $1.50 to end the day at $25.38, a gain of 2.74 percent.

Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN), Human Genome (NASDAQ:HGSI) Could be Takeover Targets

With time and costs a major factor in the drug industry, companies appear to be hunting for takeover targets like Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN) and Human Genome (NASDAQ:HGSI), which have a pipeline, or are close to developing a pipeline, with soon-to-be-approved drugs.

Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).

Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.

Onyx Pharmaceuticals' (Nasdaq:ONXX) Carfilzomib Fast-Tracked by FDA

The U.S. Food and Drug Administration (FDA) granted Onyx Pharmaceuticals' (Nasdaq:ONXX) Carfilzomib fast-track designation

Carfilzomib is the multiple-myeloma drug of Onyx Pharmaceuticals.

What this means is the review process will accelerate, and Onyx will be allowed to to submit its carfilzomib application on a rolling basis. With the fast-track, the company believes they could end the process by the middle of 2011. They already have the process in motion.

Onyx closed Monday at $35.28, gaining $0.78, or 2.25 percent.

Onyx Pharmaceuticals (NASDAQ:ONXX) Pipeline Underappreciated Says Barclays (NYSE:BCS)

Commenting on what they call Onyx Pharmaceuticals' (NASDAQ:ONXX) 'underappreciated pipeline," Barclays (NYSE:BCS) sees 2011 as a "transformative" year of Onyx.

Barclays (NYSE:BCS) said, "We are reiterating our rating on shares of ONXX following posting of BATTLE-2 trial details on ClinicalTrials.gov. Following impressive Nexavar efficacy in BATTLE-1, we continue to be optimistic about the potential for Nexavar success in MISSION with data expected next year and estimate an $800M potential in Nexavar lung revenues with - 25,000 3rd-line non-small cell lung cancer (NSCLC) patients.

"With investor focus on flagship carfilzomib, for which we expect YE11 approval to support - $1B in sales, we continue to believe 2011 will be transformative for ONXX and its underappreciated pipeline. We expect multiple milestones for Carfilzomib in myeloma and late-stage Nexavar opportunities in NSCLC, liver, thyroid, and breast coming up next year."

Barclays reiterates an "Overweight" on Onyx Pharmaceuticals, which closed Friday at $35.48, up $0.18, or 0.51 percent. They have a price target on them of $42.

Onyx Pharmaceuticals (NASDAQ:ONXX) May Take Breather

Canaccord Genuity maintains their "Buy" rating on Onyx Pharmaceuticals (NASDAQ:ONXX). but it comes with the caveat of uncertainty surrounding risks connected to the company.

Canaccord said, "We expect Dec. 6 ASH presentation of ONXX’s Phase II 003-A1 trial evaluating carfilzomib in r/r multiple myeloma to be positive, but it could leave important questions unanswered. Accordingly, despite our BUY thesis supported mostly on underappreciated value, we believe shares could take a breather...Our $34 target is based on a DCF. Risks include clinical trial failures and regulatory delays."

Onyx closed Tuesday down to $29.51, falling $0.20, or 0.67 percent. Canaccord has a price target of $34 on the company.